Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Phase 1
Terminated
- Conditions
- Retinitis Pigmentosa SyndromeRetinitis Pigmentosa
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Endogena Therapeutics, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05392751
- Locations
- 🇺🇸
Endogena Site 002, Dallas, Texas, United States
🇺🇸Endogena Site 003, Ann Arbor, Michigan, United States
🇺🇸Endogena Site 005, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath